Belite Bio, Inc American Depositary Shares BLTE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T03:16:17.184Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:42:16.252899169Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T03:16:16.826180+00:00
Belite Bio, Inc American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 179.36 | 97.7% | 16.6% | 138.86 | 95.2% | 12.7% |
| 25Δ | 171.65 | 81.7% | 11.9% | 144.64 | 78.8% | 9.2% |
| 30Δ | 167.85 | 78.2% | 9.8% | 147.45 | 77.5% | 7.9% |
| 35Δ | 164.73 | 76.8% | 8.3% | 150.06 | 77.3% | 6.8% |
| 40Δ | 162.04 | 75.0% | 7.1% | 152.46 | 76.9% | 6.0% |
| 45Δ | 159.45 | 74.0% | 6.0% | 154.87 | 76.4% | 5.1% |
| 50Δ | 157.16 | 75.3% | 5.2% | 157.16 | 75.2% | 4.3% |
| 55Δ | 154.86 | 76.6% | 4.5% | 159.45 | 74.0% | 3.6% |
| 60Δ | 152.41 | 77.8% | 3.9% | 162.00 | 74.6% | 3.0% |
| 65Δ | 149.95 | 79.1% | 3.2% | 164.63 | 75.9% | 2.5% |
| 70Δ | 147.20 | 80.1% | 2.7% | 167.05 | 74.0% | 2.0% |
| 75Δ | 144.30 | 81.5% | 2.1% | 169.45 | 71.5% | 1.5% |
| 80Δ | 140.74 | 84.6% | 1.7% | 172.35 | 69.8% | 1.1% |
20Δ
- Pseudo strike
- 179.36
- IV
- 97.7%
- B/E move
- 16.6%
- Pseudo strike
- 138.86
- IV
- 95.2%
- B/E move
- 12.7%
25Δ
- Pseudo strike
- 171.65
- IV
- 81.7%
- B/E move
- 11.9%
- Pseudo strike
- 144.64
- IV
- 78.8%
- B/E move
- 9.2%
30Δ
- Pseudo strike
- 167.85
- IV
- 78.2%
- B/E move
- 9.8%
- Pseudo strike
- 147.45
- IV
- 77.5%
- B/E move
- 7.9%
35Δ
- Pseudo strike
- 164.73
- IV
- 76.8%
- B/E move
- 8.3%
- Pseudo strike
- 150.06
- IV
- 77.3%
- B/E move
- 6.8%
40Δ
- Pseudo strike
- 162.04
- IV
- 75.0%
- B/E move
- 7.1%
- Pseudo strike
- 152.46
- IV
- 76.9%
- B/E move
- 6.0%
45Δ
- Pseudo strike
- 159.45
- IV
- 74.0%
- B/E move
- 6.0%
- Pseudo strike
- 154.87
- IV
- 76.4%
- B/E move
- 5.1%
50Δ
- Pseudo strike
- 157.16
- IV
- 75.3%
- B/E move
- 5.2%
- Pseudo strike
- 157.16
- IV
- 75.2%
- B/E move
- 4.3%
55Δ
- Pseudo strike
- 154.86
- IV
- 76.6%
- B/E move
- 4.5%
- Pseudo strike
- 159.45
- IV
- 74.0%
- B/E move
- 3.6%
60Δ
- Pseudo strike
- 152.41
- IV
- 77.8%
- B/E move
- 3.9%
- Pseudo strike
- 162.00
- IV
- 74.6%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 149.95
- IV
- 79.1%
- B/E move
- 3.2%
- Pseudo strike
- 164.63
- IV
- 75.9%
- B/E move
- 2.5%
70Δ
- Pseudo strike
- 147.20
- IV
- 80.1%
- B/E move
- 2.7%
- Pseudo strike
- 167.05
- IV
- 74.0%
- B/E move
- 2.0%
75Δ
- Pseudo strike
- 144.30
- IV
- 81.5%
- B/E move
- 2.1%
- Pseudo strike
- 169.45
- IV
- 71.5%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 140.74
- IV
- 84.6%
- B/E move
- 1.7%
- Pseudo strike
- 172.35
- IV
- 69.8%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 60.98% | |
| 61.24% | |
| 61.57% | |
| 61.76% | |
| 61.26% | |
| 61.47% | |
| 63.18% |
Biotechnology
BMEA
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically…
More →BMRN
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San…
More →BNTC
Description unavailable
More →BNTX
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
More →BYSI
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered…
More →CABA
Description unavailable
More →